These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36864023)

  • 1. A covalent BTK ternary complex compatible with targeted protein degradation.
    Schiemer J; Maxwell A; Horst R; Liu S; Uccello DP; Borzilleri K; Rajamohan N; Brown MF; Calabrese MF
    Nat Commun; 2023 Mar; 14(1):1189. PubMed ID: 36864023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes.
    Schiemer J; Horst R; Meng Y; Montgomery JI; Xu Y; Feng X; Borzilleri K; Uccello DP; Leverett C; Brown S; Che Y; Brown MF; Hayward MM; Gilbert AM; Noe MC; Calabrese MF
    Nat Chem Biol; 2021 Feb; 17(2):152-160. PubMed ID: 33199914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
    Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase.
    Harris CM; Foley SE; Goedken ER; Michalak M; Murdock S; Wilson NS
    SLAS Discov; 2018 Dec; 23(10):1040-1050. PubMed ID: 29991334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase.
    Awoonor-Williams E; Rowley CN
    J Chem Inf Model; 2021 Oct; 61(10):5234-5242. PubMed ID: 34590480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules.
    Delport A; Hewer R
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31500395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
    Sun SL; Wu SH; Kang JB; Ma YY; Chen L; Cao P; Chang L; Ding N; Xue X; Li NG; Shi ZH
    J Med Chem; 2022 Jun; 65(11):7415-7437. PubMed ID: 35594541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
    Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
    Zhang J; Che J; Luo X; Wu M; Kan W; Jin Y; Wang H; Pang A; Li C; Huang W; Zeng S; Zhuang W; Wu Y; Xu Y; Zhou Y; Li J; Dong X
    J Med Chem; 2022 Jul; 65(13):9096-9125. PubMed ID: 35671249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
    Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
    Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicyclobutane Carboxylic Amide as a Cysteine-Directed Strained Electrophile for Selective Targeting of Proteins.
    Tokunaga K; Sato M; Kuwata K; Miura C; Fuchida H; Matsunaga N; Koyanagi S; Ohdo S; Shindo N; Ojida A
    J Am Chem Soc; 2020 Oct; 142(43):18522-18531. PubMed ID: 33047956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
    Huang HT; Dobrovolsky D; Paulk J; Yang G; Weisberg EL; Doctor ZM; Buckley DL; Cho JH; Ko E; Jang J; Shi K; Choi HG; Griffin JD; Li Y; Treon SP; Fischer ES; Bradner JE; Tan L; Gray NS
    Cell Chem Biol; 2018 Jan; 25(1):88-99.e6. PubMed ID: 29129717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Su R; Diao Y; Sha W; Dou D; Yu Z; Leng L; Zhao Z; Chen Z; Li H; Xu Y
    Bioorg Chem; 2022 Sep; 126():105860. PubMed ID: 35661525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton's Tyrosine Kinase.
    Ong LL; Vasta JD; Monereau L; Locke G; Ribeiro H; Pattoli MA; Skala S; Burke JR; Watterson SH; Tino JA; Meisenheimer PL; Arey B; Lippy J; Zhang L; Robers MB; Tebben A; Chaudhry C
    SLAS Discov; 2020 Feb; 25(2):176-185. PubMed ID: 31709883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
    Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel BTK PROTACs for B-Cell lymphomas.
    Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
    Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimagining Druggability Using Chemoproteomic Platforms.
    Spradlin JN; Zhang E; Nomura DK
    Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.